CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

🤖 Plain-English Summary

METHODS: After conducting preclinical in vitro and in vivo studies, we evaluated the safety and pharmacodynamic effects of single escalating doses of NTLA-2001 in six patients with hereditary ATTR amyloidosis with polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per kilogram), within an ongoing phase 1 clinical study. At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a do...

🔑 Key Findings

• Serial assessments of safety during the first 28 days after infusion in patients revealed few adverse events, and those that did occur were mild in grade.
• Dose-dependent pharmacodynamic effects were observed.
• At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram.

🔗 Related Resources